TScan Therapeutics (NasdaqGM:TCRX) FDA Announcement November 03, 2025 08:00 AM ET Speaker0Dose range for the pivotal study. During 2025, we introduced a fourth dose level into the phase one study so that we could implement fixed dosing rather than weight-based dosing, which is preferable in the commercial setting. At this fixed dose level, patients will receive about 800 million cells in their first infusion and about 1.6 billion cells in their second infusion. In agreement with the FDA, we plan to dose and ...